Scienture Holdings, Inc. — 2023 Q1 10-Q Summary
Entity identification: The supplied filing is for TRxADE HEALTH, Inc. (NASDAQ: MEDS), not Scienture Holdings, Inc. The summary below reflects the filing’s named registrant. The unaudited quarter ended March 31, 2023; the report was signed May 15, 2023.
Business context and reporting period
TRxADE described itself as a technology-enabled healthcare platform, including a pharmaceutical marketplace, pharmaceutical wholesaling, retail pharmacy and telehealth businesses. It reported approximately 14,100 registered platform users. In January 2023, it agreed to sell its Alliance Pharma Solutions and Community Specialty Pharmacy subsidiaries for $225,000 combined, plus an estimated approximately $266,000 for services before closing. The filing describes those sales as pending at the reporting date. The company withdrew from its SOSRx joint venture in February 2023 and treated its results as discontinued operations.
Financial results and position
| Metric | Q1 2023 | Q1 2022 or prior date |
|---|---|---|
| Revenue | $2.25 million | $3.24 million; down 30.6% |
| Gross profit and gross margin | $1.56 million; 69% | $1.34 million; 41% |
| Operating loss | $347,406 | $968,572 |
| Net loss attributable to TRxADE | $677,953, including $352,244 from discontinued operations | $960,147 |
| Basic and diluted loss per share | $0.07 | $0.12 |
| Cash from operating activities | Used $931,531 | Used $1,000,771 |
| Cash at quarter-end | $1.19 million | $1.11 million at December 31, 2022, per the balance sheet |
| Total assets / total liabilities | $4.04 million / $3.38 million | $3.71 million / $3.37 million at December 31, 2022 |
Cost of sales fell 63.7%, helping lift gross profit despite lower revenue. Management attributed the margin improvement to marketplace revenue, which has no cost of goods expense, and improved wholesaler margins. Operating expenses declined 17.3%, partly reflecting lower wages and general and administrative costs. The company reported a $79,891 noncash gain from the change in warrant fair value and $62,392 of interest expense.
At March 31, 2023, working capital was negative $164,035, compared with negative $53,668 at year-end. Current liabilities were $2.55 million. The company reported no related-party notes payable at quarter-end, but had $789,286 in contingent funding liabilities and approximately $1.04 million in lease liabilities. It used $87,072 for capitalized software development. Financing activities provided $681,257, principally from future-receivables funding, partly offset by repayments.
Material changes versus the prior comparable period
- Revenue declined by $992,522, primarily reflecting reduced wholesaler sales; marketplace platform revenue increased, while Trxade Prime revenue declined approximately 11%.
- Gross profit rose by $221,377, and gross margin improved from 41% to 69%.
- Net loss attributable to the company narrowed by $282,194, although Q1 2023 included a $352,244 discontinued-operations loss related to the SOSRx withdrawal.
- Registered users rose 9% year over year to approximately 14,100; new registrations were 291 versus 339 in Q1 2022.
- Common shares outstanding increased from 9,393,708 at December 31, 2022 to 10,210,878 at March 31, 2023. The filing also reports 2,689,969 outstanding warrants and 431,425 options at quarter-end.
Outlook, risks and unusual items
- Going concern: Management stated that limited financial resources and a working-capital deficit raise substantial doubt about the company’s ability to continue as a going concern. It said additional equity or debt funding would be needed within the next 12 months and might not be available on favorable terms.
- Cash needs: The company estimated operating expenses and working-capital requirements of approximately $8 million for April 2023 through March 2024. It gave no revenue or earnings guidance.
- Funding and dilution: A March 2023 receivables financing arrangement provided funding in exchange for future receivables, with a stated effective interest rate of approximately 36%. The arrangement gives the funder priority over specified receivables and includes default provisions that could direct all future sales proceeds to repayment. Equity financing could dilute existing holders.
- Nasdaq listing: The company was below Nasdaq’s continued-listing equity requirement. After the quarter, Nasdaq granted an exception permitting continued listing while the company pursued an offering of up to $15 million; it had to demonstrate compliance by June 21, 2023. The filing also notes restrictions on using Form S-3 and the risk of delisting.
- Business changes: Management was exploring strategic alternatives for B2C subsidiaries, including sale, spin-off, financing, combination or winding down. No final decision was reported. SOSRx operations were discontinued after the company withdrew from the venture; a $500,000 note was canceled and approximately $15,000 of payables waived.
- Contingencies: After quarter-end, a court ordered Studebaker Defense Group to pay $550,000 to Integra in installments. The company reported that GSG had not made its required settlement payments since January 2023. Other disclosed litigation includes older supplier disputes over undelivered products.
- Controls and reporting: Management concluded disclosure controls were ineffective and identified material weaknesses in written accounting/reporting procedures and period-end financial reporting controls; it said remediation work was underway.
- Filing figures to reconcile: The MD&A gives December 31, 2022 cash as $1,133,633, while the balance sheet and cash-flow statement show $1,111,156. The receivables-financing disclosures also cite differing amounts: the financial-statement note describes $875,000 funded to purchase $1,224,000 of receivables, while later disclosures describe $850,000 funded and $1,124,000 of receivables. The filing text does not provide a clear reconciliation.
Important facts for investors to verify
- Confirm that TRxADE HEALTH, Inc. is the intended issuer; it is the registrant named in the supplied 10-Q, not Scienture Holdings, Inc.
- Check the closing status and actual proceeds from the proposed sales of Alliance Pharma Solutions and Community Specialty Pharmacy, and confirm subsequent Nasdaq listing compliance and any capital raise.
- Reconcile quarter-end cash and the March receivables-financing amounts, repayment terms, effective cost and default provisions against the underlying agreements and subsequent filings.
- Review the company’s cash runway against its stated $8 million next-12-month expense estimate, going-concern disclosure and continuing operating cash use.
- Assess the dilution and potential accounting effects of outstanding warrants and options, and track remediation of the disclosed control weaknesses.